Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Option Care Health to Merge With Amedisys in $3.6 Billion Deal
Option Care Health, Inc. and Amedisys, Inc. announced that they have entered into a definitive merger agreement to combine in an all-stock transaction that values Amedisys at approximately $3.6 billion, including the assumption of net debt. Upon closing, Option Care Health stockholders will own 64.5% of the combined company, and Amedisys stockholders will own 35.5%. Together, Option Care Health and Amedisys will have a national clinical workforce of more than 16,500 professionals and 674 care centers across the United States. Based on recently reported 2022 financial results, the combined company generated revenues of approximately $6.2 billion and adjusted EBITDA of approximately $622... Read More »
Provident Healthcare Partners Advises Coastal Cancer Center in OneOncology Partnership
Provident Healthcare Partners announced on May 3 it has advised Coastal Cancer Center in signing a partnership agreement with OneOncology. Coastal Cancer Center, which is led by Dr. Emily Touloukian, has six medical oncologists, a hospitalist and eight advanced practice providers. It operates out of four locations in Myrtle Beach, South Carolina. OneOncology, a portfolio company of General Atlantic, is a national network of independent community oncologists assisting partner practices to expand their cancer care services. Its network includes 850 physicians practicing at more than 180 sites, serving approximately 280,000 patients annually. The announcement follows OneOncology’s recent... Read More »
Hildred Capital Management Acquires AleraCare
New York-based private equity firm Hildred Capital Management announced on May 2 that it entered into an agreement to acquire AleraCare for an undisclosed price. AleraCare is a provider of infusion and specialty pharmacy services. Founded in 2019, AleraCare’s core lines of business includes infusions at ambulatory infusion centers, home infusion therapy, specialty pharmacy and compounding pharmacy. It has more than 35 locations in the western United States. Hildred Capital Management pursues growth equity investments in lower middle market healthcare companies with leading products, technologies and services. AleraCare will use the capital provided by Hildred to further enhance its... Read More »
Quadria Capital Acquires Majority Stake in Straits Orthopaedics
Quadria Capital has announced the acquisition of a majority stake in Straits Orthopaedics from its founder, Mr. T.H. Su, and Apex Healthcare Bhd. Kirkland & Ellis advised Quadria Capital on the debt financing for its acquisition. Under the terms of the agreement, Apex Healthcare Bhd and Su have agreed to reinvest a substantial portion of their sales proceeds back into the company as minority-stake partners. As part of the deal, Su has been reappointed as the CEO and director of the company for the next five years. Financial terms of the deal were not disclosed. Founded in 2003, Straits Orthopaedics manufactures a range of orthopedic-focused medical device solutions for blue-chip... Read More »
New Mountain Capital Acquires Apixio from Centene
New Mountain Capital announced on May 3 that it acquired Apixio Inc. from Centene Corp. for an undisclosed price. According to data captured in the LevinPro HC database, this acquisition represents the 100th eHealth transaction of the year, and the 15th in the analytics specialty. William Blair is serving as Centene’s financial adviser and Bass, Berry & Sims, PLC as its legal counsel. J.P. Morgan Securities LLC is serving as financial adviser to New Mountain Capital, and Ropes & Gray LLP is serving as its legal counsel. Apixio provides a technology suite that mines, compiles and analyzes large volumes of disparate, unstructured patient data (such as physician notes and... Read More »
Stryker Acquires Cerus Endovascular
Stryker Corp. announced on May 2 that it completed its acquisition of Cerus Endovascular Ltd. According to data captured in the LevinPro HC database, this represents the 41st Medical Devices transaction of the year. Cerus Endovascular is a privately held, commercial-stage, medical device company engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Stryker develops, manufactures and markets specialty surgical and medical products. These include orthopedic implants, powered surgical instruments, endoscopic systems and patient care and handling equipment. Stryker impacts more than 130 million patients annually. Stryker’s... Read More »
Bonatra Acquires Femtech Startup MyAva
Healthcare start-up Bonatra announced on May 2 its acquisition of women’s health and wellness company MyAva for an undisclosed amount. According to data captured in the LevinPro HC database, this acquisition represents the 98th eHealth transaction of 2023, including 20 in the telehealth specialty. There were 150 eHealth and 21 telehealth deals announced between January 1, 2022, and May 2, 2022. Through this acquisition, Bonatra aims to expand its healthcare programs and become a one-stop platform for the management of chronic health conditions. Terms of the deal were not disclosed. Founded in 2019 by Evelyn Immanuel, MyAva is a femtech start-up that offers curated programs and... Read More »
Medical Specialists of the Palm Beaches Acquires Cohen Medical Associates
Medical Specialists of the Palm Beaches (MSPB), backed by Ascend Partners and CareAbout Health, announced on May 2 that it acquired Cohen Medical Associates. Cohen Medical Associates provides complete family healthcare including routine visits, laboratory testing needs and emergency appointments. Combined, the staff has more than 100 years of medical experience. It has one location in Delray Beach, Florida. MSPB is a primary care-focused, multi-specialty physician group practice in South Florida. It has a team of more than 95 providers. This acquisition will increase MSPB’s primary care provider network by approximately 15% and will support Cohen Medical Associates’... Read More »
Astellas Pharma to Acquire Iveric Bio for $5.9 Billion
Astellas Pharma announced that it has entered into a definitive agreement to acquire Iveric Bio for $40 per share in cash, for a total equity value of approximately $5.9 billion. The acquisition is expected to be completed in the third quarter of 2023. Under the terms of the agreement, Iveric Bio will become an indirectly wholly owned subsidiary of Astellas Pharma. The acquisition includes avacincaptad pegol, which is under evaluation for the treatment of geographic atrophy. Iveric Bio is a biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The company delivers treatments designed to address... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
